News

It also announced the appointment of former Novartis Oncology SVP Brian Gladsden as CEO. The firm raised the amount from Syncona Investment Management, and Cambridge Innovation Capital. Proceeds

The gene therapy is used for the treatment of inherited retinal disease (IRDs) caused by RPE65 mutations. Retina is impacted in patients who suffer from RPE65 mutation-associated IRDs and

Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head

As part of the deal, both the entities will be involved in research activities to detect and improve LENSai in silico-generated antibodies. These antibodies are being developed as

The independent bid committee of Sensidose has recommended the cash offer. At present, the shares of Sensidose are listed on Spotlight Stock Market in Sweden. Sensidose is involved

As per the terms of the deal, OEP will receive exclusive rights from OncoVent to commercialise oregovomab in Taiwan. The licence will also cover related regulatory applications and

ENHERTU, which is a HER2 directed ADC, features a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload through a stable tetrapeptide-based cleavable linker. The approval of

A tumour infiltrating lymphocyte (TIL) therapy,  lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced  on or after prior anti-PD-1/L1 therapy and targeted therapy.

Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates against a new target leveraging its Enigmac macrophage drug discovery platform. Ono Pharmaceutical